BioCardia To Release Third Quarter 2021 Financial Results November 10, 2021
BioCardia, Inc. (NASDAQ:BCDA), a developer of cell-derived therapeutics for cardiovascular and pulmonary diseases, will release its third quarter 2021 financial results on November 10, 2021, at 4:30 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioCardia, Inc. (NASDAQ:BCDA), a developer of cell-derived therapeutics for cardiovascular and pulmonary diseases, will release its third quarter 2021 financial results on November 10, 2021, at 4:30 PM ET. The company focuses on two biotherapeutic platforms: CardiAMP for cardiovascular indications and NK1R+ for potential treatments in cardiovascular and pulmonary diseases. These platforms support four product candidates aimed at benefiting millions of patients.
Details
News Market Reaction – BCDA
The recorded move for BCDA in the trading session of this news was -1.08%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN CARLOS, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a company focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces it will release third quarter 2021 financial results on Wednesday, November 10, 2021 at 4:30PM ET.
About BioCardia®
BioCardia, Inc., headquartered in San Carlos, California, is a developer of two biotherapeutic platforms – the CardiAMP autologous bone marrow derived mononuclear cell therapy for cardiovascular indications, and the NK1R+ allogenic bone marrow derived mesenchymal stem cell therapies for cardiovascular and pulmonary diseases. These platforms underlie four product candidates, each with the potential to meaningfully benefit millions of patients. Three of these investigational therapies are enabled by the Company’s proprietary biotherapeutic delivery platforms, which the Company also selectively licenses to other biotherapeutic development firms.
INVESTOR CONTACT:
David McClung, Chief Financial Officer
investors@BioCardia.com, (650) 226-0120
MEDIA CONTACT:
Anne Laluc
alaluc@BioCardia.com, (650) 226-0120
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.